Feldman,D.N.The LancetSwaminathan RV, Feldman DN. TRILOGY ACS: prasugrel of benefit only after angiography? Lancet. 2013;382:580-582.Swaminathan RV, Feldman DN. TRILOGYACS: prasugrel of benefit only after angiography? Lancet 2013;382:580-582....
White HD, Westerhout CM, Alexander KP, Roe MT, Winters KJ, Cyr DD, Fox KA, Prabhakaran D, Hochman JS, Armstrong PW, Ohman EM; TRILOGY ACS Investigators. Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: insights from the TaRgeted platelet ...
Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization The TRILOGY ACS Platelet Functi... Context The relationship of platelet function test PA Gurbel,D Erlinge,EM Ohman,... - 《Jama the Journal of the American Medical Association》...
Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Husted S, Boersma E. Am J Ther. 2016 Nov/Dec;23(6):e1876-e1889. doi: 10.1097/MJT.0000000000000237. PMID: 25830867 Free PMC article. Review. See...
BackgroundIn the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial of patients with non-ST-segment elevation acute coronary syndrome managed medically without revascularization, treated with prasugrel versus clopidogrel for less than...
Rajesh V SwaminathanDivision of CardiologyDmitriy N FeldmanDivision of CardiologyThe LancetSwaminathan RV, Feldman DN. TRILOGY ACS: prasugrel of benefit only after angiography? Lancet. 2013;382:580-582.Swaminathan RV, Feldman DN. TRILOGYACS: prasugrel of benefit only after angiography? Lancet 2013;...
Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: Insights from the TRILOGY ACS trialKeywords acute coronary syndromeADP receptor antagonistoutcomeBackground: Certain alleles of the CYP2C19 gene are associated with higher platelet reactivity and increased ischemic events a...
TRILOGY-ACS shows no advantage for prasugrel over clopidogrelJulinda MehilliTime to primary PCI
doi:10.1097/MJT.0000000000000237Steen HustedEric BoersmaHusted S, Boersma E. Case Study: Ticagrelor in PLATO and Pra- sugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes. Am J Ther. 2015; [Epub ahead of print]....
Consider potential risks Drs Floyd and Serebruany say that, while the US FDA has mandated that baseline cancer history and cancer event data be collected in the TRILOGY-ACS* an ongoing study comparing prasugrel with clopidogrel in patients with acute coronary syndrome, the agency must insist as ...